to performing the transplant as early as possible. Practically speaking, this means that when such therapy is chosen for a patient with CR1 AML, the search for an Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indiallogeneic donor should begin immediately and transplant be performed as soon as possible. cations for this therapy mainly rely upon prognostic factors, and their importance is constantly reassessed. To Keywords: allogeneic transplant; AML; outcome examine the impact of time from diagnosis to transplant on survival and leukemia-free survival (LFS), we analyzed 109 patients from the database of the SFGM comCurrently, complete remission (CR) is achieved in approxiprising patients who had all received an HLA-identical mately 70% of adult patients with AML. 1 For such patients, allogeneic BMT for a diagnosis of AML in first complete the most important issue is to decide the post-induction remission (CR1) between January 1987 and December treatment most likely to maintain this remission. 2-4 When 1992. All patients were conditioned with cyclophosa young patient has an HLA-identical sibling, allogeneic phamide (CY) and total body irradiation (TBI) (CY-(allo) bone marrow transplantation (BMT) is the preferred TBI), and methotrexate (MTX) ؉ cyclosporin A (CsA) antileukemic consolidation therapy. 5, 6 However, the controwere used as graft-versus-host disease (GVHD) prophyversy is whether or not to use BMT as first-line therapy, laxis. Patient characteristics were: age = 33 ؎ 9, M/F = because of transplant-related mortality (TRM), as it has 64/45, white blood cell count (WBC) at diagnosis = 27 been shown that intensive chemotherapy may give a com-؎ 42 ؋ 10 9 /l, FAB distribution: M1 and M2 = 55; M3 parable ultimate survival rate, especially if high-dose cytar-= 15, M4 and M5 = 33, M0, M6 and M7 = 6. Karyotypabine is included. 4, 7,8 In choosing this latter option, BMT ing was carried out for 64 patients: 32 had a normal is then considered after relapse. However, this sequential karyotype, 16 had good prognosis abnormalities strategy suffers from potential drawbacks. Most often, for (t(8;21), t(15;17), inv 16) and 16 patients had other reasons of patient status, logistical problems, or refractory abnormalities. Eleven patients needed two courses of disease, it is not possible to transplant such patients after induction to achieve CR. Time between diagnosis and relapse, making such rescue strategy globally ineffective.
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BMT was 120 (64-287) days. Forty-nine patients
In addition, the antileukemic effect of allo BMT is less developed grade у у у2 acute GVHD (actuarial probability efficient in more advanced disease. 9 = 46%). With a median follow-up of 50 months (27-We have recently analyzed a cohort of patients from the 100), the 5-year probabilities for transplant-related SFGM registry for whom allo BMT was considered as the mortality (TRM), relapse, overall survival and LFS are consolidation therapy of choice and carried out within 100 respectively 25%, 26%, 59% and 55%. A multivariate days of diagnosis. 10 We showed that these patients had a analysis showed that survival is adversely influenced by long-term outcome superior to any chemotherapy regimen three independent factors: time to transplant (Ͼ Ͼ Ͼ120 or autologous (auto) BMT strategy. Although these results days vs р р р120 days), acute GVHD (grade 2-4 vs grade are encouraging and possibly related to early transplant, 0-1) and age (Ͼ Ͼ Ͼ33 vs р р р33). LFS is only influenced by they may also relate to other factors undetected in the the first two of these factors. The favorable impact of a analysis of this highly selected population. In an attempt to shorter time from diagnosis to transplant should lead reduce this possibility and ultimately to study the impact of this factor in relationship to others, we returned to the phosphamide (CY) and total body irradiation (TBI) (CYpatients, who were transplanted in 25 centers, were reviewed. Forty-two of these patients have been previously TBI) and had received GVHD prophylaxis with cyclosporin A (CsA) and short methotrexate (MTX). In this cohort of reported. 10 The marrow donor population consisted of 59 males and 50 females. A donor-recipient sex mismatch 109 patients, overall, we found that delay from diagnosis to transplant appeared to have a major impact on both overall existed in 47 cases, and ABO groups were mismatched in 40 cases. survival and leukemia-free survival (LFS).
Patients and methods

Preparative regimen Patients and donors
All patients first received 60 mg/kg CY i.v. on each of 2 From 1984 to 1992, 444 adult patients with AML in CR1 successive days, followed by TBI which was delivered were reported to the SFGM registry. In order to study the either as a single fraction (single dose TBI or STBI) for 22 outcome of patients transplanted only according to a unipatients, or in several factions (fractionated TBI or FTBI) form strategy, we selected a population from the database for 87 patients. Total TBI doses delivered ranged from 9 according to the following criteria:
to 13 Gy at mid-abdomen (average = 11.7 Ϯ 1). Lung shielding was carried out in all cases at a cumulated dose • BMT performed after 1 January 1987 (n = 347); of 8 Gy. The number of fractions ranged from 3 to 6 in the • received a graft from HLA-A, -B, -DR, identical and case of FTBI (median = 5). negative mixed lymphocyte culture (MLC) sibling (n = 331);
• similar BMT procedure for conditioning regimen (only GVHD prophylaxis CY and TBI; n = 142) and for GVHD prophylaxis (only a short course of MTX and CsA) (n = 122).
11
All patients received a combination of MTX and CsA as A subgroup of 109 patients satisfied all these criteria and GVHD prophylaxis. 11 No patient received a T cell-depleted their characteristics are shown in Table 1 . Data from these marrow or any other additional GVHD prophylaxis. The analysis was conducted in July 1995 after a minimum M0, M6, M7 6 (6) follow-up of 30 months. Survival was calculated from the causes if not (transplantation-related mortality = TRM).
(range)
The probability of relapse was calculated from day 0 until ences among groups.
Results
and Ͼ120 days). Patient, disease, and transplant characteristics do not notably differ between the two groups (Table 4) . Survival and LFS (Figures 2 and 3 ) are higher Four patients died prior to engraftment and 105 achieved hematological recovery with a granulocyte count above for the patients transplanted earlier (P Ͻ 0.04). These differences seem to result from an increase in the rate of 0.5 ϫ 10 9 /l and platelet transfusion independence. A median of 19 days (range 11-41) was needed to reach relapse and transplant-related mortality in the group of patients transplanted after 120 days (relapse: 18% vs 36% 0.5 ϫ 10 9 granulocytes/l. A median of 27 days (range 9-287) was needed to reach 50 ϫ 10 9 platelets/l without trans-P = NS, transplant-related mortality: 17% vs 33% P = NS), but these differences do not reach significance. fusions.
Seventy patients developed aGVHD, with moderate to severe effects (grade у2) in 49 patients (actuarial KaplanMeier probability = 46%). Of the 94 patients who were Discussion evaluable for cGVHD, 31 (36%) developed clinical cGVHD requiring immunosuppressive therapy.
While its antileukemic effect is well acknowledged, the place of allogeneic BMT in the treatment of AML remains With a median follow-up of 52 months (range 30-100), 66 patients were alive, of whom 62 were in complete concontroversial. [15] [16] [17] [18] Recent progress in intensive chemotherapy, most notably by using high-dose cytarabine or tinuous remission. Relapse occurred in 20 patients at a median of 18 months (range 2-62) giving a 26% 5-year autologous BMT, or both, seems to be associated with higher survival rates. 8,19-21 However, relapse remains a actuarial probability of relapse. Four patients who relapsed are still alive, in second complete remission, with a 16-35 major problem. Furthermore, treatment utilizing this intensity of chemotherapy frequently precludes the possibility of month follow-up post relapse. A second allogeneic BMT was performed for two of them. In a univariate analysis, rescue by allo BMT after an early relapse in patients, for whom a donor is available, because of cumulative toxcGVHD was associated with a trend towards lower relapse rates, but this was not significant (P = 0.06). Relapse was icities. Taken together, this means that in the case where allo BMT is possible, the choice of therapy must be made eventually the cause of death in 16 of the 43 patients who died. The other 27 deaths were related to transplantation as early and does not really allow any crossover of these intensive strategies for most patients. shown in Table 1 . This resulted in an overall 5 year TRM of 25% (range 17-34) which, in univariate analysis, was
The proportion of patients for whom an allo BMT is a real option, represents approximately 10% of all patients influenced by age (р33 years; 13% vs Ͼ33 years; 36% (P Ͻ 0.05)) and moderate to severe acute GVHD (grade 0-suffering from AML. Since these patients, in terms of age and availability of an HLA-identical donor, are young, 1: 14% vs grade у2: 38% (P Ͻ 0.05)). Figure 1 shows the actuarial probability of survival, TRM, LFS and relapse.
meaning that their life expectancy would be estimated in decades were it not for their AML, it seems warranted that Variables favoring the probability of overall survival and LFS as well as a multivariate analysis are shown in they be given special consideration. This includes new and specific efforts to decrease the risks of transplant-related Tables 2 and 3 . In this analysis, time from diagnosis to transplant and occurrence of moderate to severe aGVHD toxicity. Supportive care is constantly improving, including more effective prophylaxis and treatment of viral and funwere identified as the most significant predictive factors (Tables 2 and 3). gal infections. 22, 23 The possibility of using allogeneic peripheral stem cell transplantation may also reduce transplantWe further analyzed two groups of patients according to the time elapsed between diagnosis and BMT (р120 days related morbidity and mortality and is currently under investigation. [24] [25] [26] Optimizing prompt access to BMT for this population must also be given priority. We have recently shown that, for patients with AML in CR1 reported in the SFGM registry, an early transplant (ie within 100 days of diagnosis), was associated with an improved longterm outcome. In order to assess better if the time from diagnosis to transplant is an important prognostic factor, we analyzed the impact of this factor on the outcome for the whole population of AML patients in CR1 transplanted with a similar procedure and within the same chronological period. Thus, all patients receiving CY and TBI as the preparative regimen and MTX and CsA as sole GVHD prophylaxis between 1987 and 1992 were included. It may be noted that during this period, 109 patients fulfilled all these criteria in the registry, while 60 patients were prepared with a busulfan-cytoxan regimen in a prospective study 6 and were not analyzed in the present report. With actuarial probabilities for TRM, relapse, survival, and LFS of respectively 25%, 26%, 59% and 55%, the out- aGVHD and age to be predictive of TRM and survival. been fully studied or recognized as a major factor influencing overall transplantation outcome as it has been for Furthermore, grade у2 aGVHD was associated with a decreased LFS. 30, 31 No factor was identified which statistipatients transplanted for CML in first chronic phase. 33 In our analysis, this factor seems to be just as important as cally influenced relapse rate. However, despite the small study population, a trend towards the protective effect of aGVHD. We demonstrate that patients transplanted prior to day 120 had superior survival and LFS probabilities. This cGVHD was seen.
We introduced the element of time elapsed between diagappears to be due to lower toxicity as well as a lower relapse rate, although these two differences do not indepennosis and BMT into our analysis. With the exception of some recent reports on leukemia, 6 ,10,20,32 this factor has not dently reach statistical significance. A decrease in toxicity 
